Marshall Wace
SPRY icon

Marshall Wace’s ARS Pharmaceuticals SPRY Stock Holding History

Marshall Wace’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$991K Buy
123,714
+18,708
+18% +$161K ﹤0.01% 2193
2026
Q1 		$843K Buy
105,006
+25,792
+33% +$247K ﹤0.01% 2212
2025
Q4 		$923K Sell
79,214
-118,106
-60% -$1.15M ﹤0.01% 1975
2025
Q3 		$1.98M Buy
197,320
+157,406
+394% +$2.26M ﹤0.01% 1630
2025
Q2 		$697K Sell
39,914
-116,721
-75% -$1.68M ﹤0.01% 2012
2025
Q1 		$1.97M Buy
156,635
+103,729
+196% +$1.25M ﹤0.01% 1468
2024
Q4 		$558K Sell
52,906
-24,973
-32% -$350K ﹤0.01% 1993
2024
Q3 		$1.13M Buy
+77,879
New +$926K ﹤0.01% 1606
2023
Q3 		– Sell
-74,621
Closed -$500K – 2652
2023
Q2 		$500K Buy
74,621
+35,193
+89% +$235K ﹤0.01% 1987
2023
Q1 		$257K Buy
39,428
+7,417
+23% +$57K ﹤0.01% 2348
2022
Q4 		$273K Buy
+32,011
New +$208K ﹤0.01% 2595
2021
Q4 		– Sell
-275,567
Closed -$2.75M – 4261
2021
Q3 		$2.75M Buy
+275,567
New +$6.8M 0.01% 1322

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Marshall Wace's SPRY Position: Q2 2026 in Review

Marshall Wace increased its ARS Pharmaceuticals (SPRY) stake by 18% in Q2 2026, buying an estimated $161K and bringing the position to 123,714 shares worth $991K. The position accounts for ﹤0.01% of the portfolio, ranked #2193.

Marshall Wace first reported a position in SPRY in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.75M in Q3 2021. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Marshall Wace held 123,714 shares of ARS Pharmaceuticals worth $991K as of Q2 2026.
  • Marshall Wace bought 18,708 ARS Pharmaceuticals shares in Q2 2026, an estimated $161K.
  • ARS Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2193 holding.
  • Marshall Wace first reported a position in ARS Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
  • Marshall Wace's ARS Pharmaceuticals position peaked at $2.75M in Q3 2021.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.